By: Dr. Avi Verma

Patients using GLP-1 agonist medications—such as Ozempic, Wegovy, and Mounjaro—for weight loss are being advised to monitor liver function closely, following reports of drug-induced hepatitis and other liver-related side effects.

A number of individuals have reported experiencing symptoms such as fatigue, flu-like symptoms, abdominal discomfort, nausea, and vomiting, which in rare cases have been linked to liver inflammation. These concerns have prompted health experts to urge regular check-ups with primary care physicians for individuals using these medications.

Emerging case reports

In Australia, several reports submitted to the Therapeutic Goods Administration (TGA) involved patients who developed hepatitis or liver injury while on semaglutide-based therapies like Ozempic and Wegovy. While such reactions are considered uncommon, experts have noted that certain individuals may have difficulty metabolizing GLP-1 agonists, potentially leading to hepatotoxicity, a form of liver toxicity caused by medications.

Social media forums and patient groups have also surfaced anecdotal accounts of similar experiences, including one user hospitalized with liver inflammation allegedly linked to Mounjaro. Another individual noted liver issues that required discontinuation of their prescribed medication.

Medical community’s response

Dr. Gary Deed of the Royal Australian College of General Practitioners emphasized the importance of monitoring liver health, especially when starting new medications. “While most patients tolerate these drugs well, liver function monitoring is prudent. Side effects such as nausea may obscure underlying hepatic issues,” he said.

Although global data indicates these liver-related side effects are rare, emerging case reports highlight the need for vigilance and further clinical research.

What patients should know

• GLP-1 receptor agonists like semaglutide mimic natural hormones that regulate insulin, appetite, and digestion.
• Anyone experiencing unusual fatigue, yellowing of the eyes or skin, abdominal pain, or persistent nausea while on these medications should consult their physician immediately.
• Patients are encouraged to schedule regular check-ups and blood tests to monitor liver enzymes and overall health.

The TGA and similar health authorities advise patients to report any suspected adverse drug reactions to their healthcare provider and national regulatory bodies.

Disclaimer:
This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional before starting or discontinuing any medication. The IndoUS Tribune does not endorse or recommend any specific drug or treatment. The information presented is based on publicly available reports and expert opinions and is not affiliated with or derived from any proprietary content.